title: Improved procedural results in coronary thrombosis are obtained with delayed percutaneous coronary interventions.
abstract: We investigated the efficacy of percutaneous coronary intervention (PCI) in coronary thrombotic lesions according to the timing of the procedure. Eighty-two patients who underwent immediate PCI (IPCI) were compared to 24 patients who underwent PCI 4.9   3 days after the diagnostic catheterization [delayed PCI (DPCI)]. DPCI was associated with a lower rate of thrombus-related angiographic events (4% versus 27%; p < 0.03), including coronary embolism (0% versus 7%; p = NS), no-reflow phenomenon (0% versus 8%; p = NS), acute closure (0% versus 10%; p = NS), stent thrombosis (4% versus 1%; p = NS) and residual thrombus (0% versus 17%; p = 0.03). No differences were seen in the hospital clinical outcome, including non-fatal myocardial infarction (4% versus 9%; p = NS), death (4% versus 0%; p = NS) or major bleeding (4% versus 3%). Delayed PCI after pharmacological treatment is a safe and efficient strategy of treatment for coronary thrombus.
authors.affiliation: Cardiology Department, Soroka Medical Center, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel. cafricar@clalit.org.il
authors.forename: Carlos
authors.initials: C
authors.lastname: Cafri
authors.forename: Ran
authors.initials: R
authors.lastname: Svirsky
authors.forename: Julian
authors.initials: J
authors.lastname: Zelingher
authors.forename: Osvaldo
authors.initials: O
authors.lastname: Slutky
authors.forename: Sergio
authors.initials: S
authors.lastname: Kobal
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Weinstein
authors.forename: Reuben
authors.initials: R
authors.lastname: Ilia
authors.forename: Harel
authors.initials: H
authors.lastname: Gilutz
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000628:therapy*; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007557:Israel; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D006493:Heparin; D000077284:Abciximab